SXLV:LSE:LSE-SPDR S&P U.S. Health Care Select Sector UCITS (USD)

ETF | Others |

Last Closing

USD 44.7375

Change

-0.16 (-0.36)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-2.81 (-1.03%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+5.50 (+2.66%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-1.11 (-0.74%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.11 (-0.78%)

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.17 (-0.98%)

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.30 (-0.47%)

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.21 (-0.70%)

USD 218.91B
0QZ3:LSE Qualcomm Inc.

-3.51 (-2.13%)

USD 202.26B

ETFs Containing SXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.06% 60% D- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.06% 60% D- 60% D-
Trailing 12 Months  
Capital Gain 16.80% 65% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.80% 65% D 63% D
Trailing 5 Years  
Capital Gain 64.05% 75% C 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.05% 75% C 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.25% 68% D+ 70% C-
Dividend Return 11.25% 67% D+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.53% 64% D 79% B-
Risk Adjusted Return 106.88% 95% A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike